Biogen's recent decision to halt Aduhelm comes as a culmination of a series of controversies and challenges that have plagued the drug since its inception.

Explore the nuances of low net cost formularies in drug pricing, the role of PBMs, and the impact of popular drugs like Humira on healthcare costs.

Nuwae was included among a list of Connecticut startups to watch compiled by the Startup Hustle podcast and published in Inc. Magazine.

FutureRx (FRx) and Nuwae, a member of the Goodroot community of companies, announced today the addition of Nuwae’s pharmacy and medical rebate services and software to the FutureRx Marketplace, providing FRx health plan and pharmacy benefits manager (PBM) customers with streamlined access to rebate optimization and management solutions.

Nuwae president Ralph Pisano and Goodroot CEO Mike Waterbury recently joined host Jonah Comstock on the pharmaphorum podcast to discuss drug pricing, the unsustainable continuous increase of healthcare premiums, the outlook for biosimilars on pharmacy spend and more.

Uncover what could happen with Humira and the biosimilar market in 2023. While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market. Will biosimilar competitors increase competition, lower drug costs and knock Humira out of the top spot? It’s the top question our clinical pharmacists and industry experts are being asked to comment on. We’re sharing all the facts—and some of our own predictions—in our webinar.

Nuwae, a company focused on reinventing patient drug access and affordability, has joined the Goodroot community of companies and its commitment to lowering healthcare costs. Ralph Pisano, who has been president of Goodroot affiliate company RemedyOne since 2020, will assume the role of president of Nuwae.

The clinical team from Goodroot and its affiliate companies — including RemedyOne, AlignRx, and Nuwae — published a whitepaper that includes projections showing Humira biosimilars gaining up to 5 percent market share in the first year, and reaching a maximum of 20-25 percent by 2026.